Nicolet Advisory Services LLC Lowers Stake in CVS Health Co. (NYSE:CVS)

Nicolet Advisory Services LLC lessened its position in CVS Health Co. (NYSE:CVS - Free Report) by 39.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,573 shares of the pharmacy operator's stock after selling 4,895 shares during the period. Nicolet Advisory Services LLC's holdings in CVS Health were worth $364,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CVS. TD Private Client Wealth LLC boosted its holdings in shares of CVS Health by 28.7% during the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator's stock valued at $2,951,000 after acquiring an additional 10,465 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock worth $90,200,000 after purchasing an additional 66,244 shares during the last quarter. Hall Laurie J Trustee raised its stake in CVS Health by 25,484.4% during the 4th quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock valued at $517,000 after buying an additional 11,468 shares during the last quarter. B&D White Capital Company LLC bought a new position in shares of CVS Health during the 4th quarter valued at $417,000. Finally, Watts Gwilliam & Co. LLC boosted its stake in shares of CVS Health by 9.8% in the 4th quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator's stock worth $334,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS traded down $0.69 during mid-day trading on Thursday, hitting $69.49. 4,023,514 shares of the stock were exchanged, compared to its average volume of 11,682,892. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market cap of $87.61 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $73.18. The firm has a 50-day moving average of $64.58 and a two-hundred day moving average of $58.35.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, equities analysts predict that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.83%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health's payout ratio is 72.68%.

Insider Transactions at CVS Health

In other news, Director Michael F. Mahoney purchased 30,000 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a report on Friday, March 21st. Wolfe Research upped their target price on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Mizuho lifted their price target on shares of CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research note on Wednesday. Cantor Fitzgerald upgraded CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. Finally, Leerink Partners raised CVS Health from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $55.00 to $75.00 in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $70.94.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.